Early bird registration is open and closes May 2025. Register now
Agenda: Chairperson: Prof. Hidekata Yasuoka 08:30-08:31 Welcome Remarks: Introduction 08:31-09:15 Current Status and Future Perspectives of Precision Medicine in Rheumatoid Arthritis Dr Keishi Fujio
Synopsis: Rheumatoid arthritis is associated with an elevated risk of sarcopenia due to pro-inflammatory cytokines, such as TNF-α.TNF inhibitors have the potential to mitigate sarcopenia
Synopsis: The presentation will include “the epidemiology, risk factors and pathological mechanism of RA-ILD”, “the current screening, monitoring and treatment for RA-ILD, such as the
Objectives: To highlight key milestones and innovations that have transformed lupus care over the past decades To review and evaluate current standard-of-care practices in SLE
Synopsis: This luncheon symposium is to Share latest cases to improve patient/ physician communications to deliver optimal treatment Showcase various Olumiant real world data across
Agenda: Chairperson: Prof. Yuko Kaneko 08:30-08:35 Welcome Remarks: Introduction 08:35-09:15 Celebrating 20 Years of IL-6 Inhibition: Past Milestones and Future Directions in RA Prof Masataka
Agenda: Chairperson: Prof. Shingo Nakayamada 11:10-12:15 Improving patient outcomes and changing the landscape in EGPA treatment – Lessons learned with Mepolizumab A/Prof. Tomohiro Koga
Agenda: Chairperson: Masataka Kuwana 11:10-12:15 Update on SSc-ILD Prof Oliver Distler
Synopsis: This symposium will explore how we can prioritise remission as the primary treatment goal for patients with systemic lupus erythematosus (SLE) and its importance
Agenda: AOSD and sJIA are Still’s disease with different time of onset. However, no consistent and standardized treatment has been established for Still’s disease. The
